From Vision to Trials: seven years of bold science
One mission taking shape: turning pioneering oligonucleotide science into therapeutic candidates with the potential to reach patients.
Read story →
Excellence-driven commitment to your health. A new generation of tailor-made oligonucleotide therapeutics built on our patented ESiNAR-X® platform – exclusive therapeutic intervention against molecular targets, without treatment-induced toxicity.
We strive to bring safe and reliable treatment modalities to patients with unmet medical need – transforming the promise of modern science.
Selecta Biotech SE is a European joint-stock company founded to improve patient health care through the development of safe, next-generation oligonucleotide therapeutics. Built on innovative science, the company is working to bring highly selective therapies into clinical practice with the goal of maximizing therapeutic benefit while minimizing treatment-related toxicity.
We collaborate with regional partners to establish a biotechnological ecosystem supporting interdisciplinary biomedical research.
Unlike conventional therapeutics, oligonucleotides recognise and bind to messenger RNA. By promoting its degradation or preventing further processing, they stop disease-causing proteins from being produced in the first place.
Recognises exclusively the target RNA – does not interfere with homologous RNA off-targets.
Preclinical studies show excellent tolerability and no treatment-induced toxicity.
Fully adaptable to different target RNAs – one modular platform, many programs.
A single technology platform powers a growing pipeline of therapeutic candidates targeting diseases with significant unmet medical need.
A precision oligonucleotide therapy designed to offer a new treatment option for patients with therapy-resistant chronic myeloid leukemia.
Explore oncology →
A potent oligonucleotide antiviral designed to target conserved viral RNA sequences to disrupt genome integrity and stop viral replication at its source.
Explore infectious diseases →
A specific oligonucleotide designed to inhibit a central pathway in renal fibrosis and prevent progression to advanced chronic kidney disease.
Explore renal diseases →Our scientific advances are supported by collaborations with leading European research institutions and organizations, driving the development of innovative oligonucleotide therapeutics.
Innovation & Excellence Awards.
Research & Development Awards.
Innovation & Excellence Awards.
Through collaborations with hospitals, research institutes, and academic partners across Slovakia and Europe, we translate scientific discoveries into differentiated therapeutic solutions.
This project was supported under the Recovery and Resilience Plan of the Slovak Republic · Innovation voucher no. 09I02-03-V03-00366.
One mission taking shape: turning pioneering oligonucleotide science into therapeutic candidates with the potential to reach patients.
Read story →Reflections from Düsseldorf, where encounters with clinicians, innovators and partners brought new perspective, pride and renewed belief in what our science can make possible for patients.
Read story →Notes from the Oligonucleotide Therapeutics Society – a field in motion, and a community increasingly connected by the possibilities ahead.
Read story →Whether you are an investor, research partner, or future colleague, we would be glad to hear from you. We welcome conversations with people who share our interest in advancing oligonucleotide therapeutics and developing safer medicines.